• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[接种疫苗的哥伦比亚人与具有登革热免疫力的未接种疫苗者体内的黄热病病毒17D中和抗体]

[Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].

作者信息

Gómez Sergio Y, Ocazionez Raquel E

机构信息

Centro de Investigaciones en Enfermedades Tropicales, Universidad Industrial de Santander, Bucaramanga, Colombia.

出版信息

Rev Salud Publica (Bogota). 2008 Nov-Dec;10(5):796-807. doi: 10.1590/s0124-00642008000500012.

DOI:10.1590/s0124-00642008000500012
PMID:19360228
Abstract

OBJECTIVE

Determining the frequency of yellow fever seroprotective antibody neutralising titres (YF-NT >or=1:10) in Colombians vaccinated with the 17 D virus and ascertaining the extent to which YF virus can be neutralised by dengue antibodies.

MATERIALS AND METHODS

Serum samples were taken from 100 subjects who showed their vaccination record and from 116 residents in municipalities (Norte de Santander) affected by a wild YF outbreak in 2002-2003 who were reported to have been YF vaccinated. Sera from individuals with (n=61) and without (n=16) dengue antibodies who had never been YF vaccinated were included. All the sera were tested by 75 % YF plaque-reduction neutralization test.

RESULTS

YF-NT titres >or=1:10 were founded in 90 % of subjects with vaccination recorded with minors variations in relation to age. In contrast, there was correlation between decrease of seroprotective YF-NT titres frequency and increase of immunization time (r=0.95; p=0.04). In residents in YF endemic area, YF-NT titres >or= 1.10 were founded in 92,6 % adults and 69 % children. YF 17 D virus was neutralized (52-100 %) by dengue sera more efficiently than non-dengue immune sera (p<0.001).

CONCLUSIONS

Individuals immunised with YF vaccine 17 D could not be protected against YF: up to 31% children and 10 % adults. Dengue antibodies inhibited YF virus and its significance in terms of YF protection must be investigated.

摘要

目的

确定接种17D病毒疫苗的哥伦比亚人中黄热病血清保护性抗体中和效价(黄热病毒中和效价≥1:10)的频率,并确定登革热抗体对黄热病毒的中和程度。

材料与方法

从100名出示疫苗接种记录的受试者以及2002 - 2003年受黄热病野生疫情影响的市镇(北桑坦德省)的116名居民中采集血清样本,这些居民据报告已接种黄热病疫苗。纳入了从未接种过黄热病疫苗但有(n = 61)和没有(n = 16)登革热抗体的个体的血清。所有血清均通过75%黄热病毒蚀斑减少中和试验进行检测。

结果

在90%有疫苗接种记录的受试者中发现黄热病毒中和效价≥1:10,且与年龄有微小差异。相比之下,血清保护性黄热病毒中和效价频率的降低与免疫时间的增加之间存在相关性(r = 0.95;p = 0.04)。在黄热病流行地区的居民中,92.6%的成年人和69%的儿童黄热病毒中和效价≥1:10。登革热血清比非登革热免疫血清更有效地中和黄热17D病毒(52 - 100%)(p < 0.001)。

结论

接种黄热病17D疫苗的个体无法得到对黄热病的保护:高达31%的儿童和10%的成年人。登革热抗体抑制黄热病毒,其在黄热病保护方面的意义必须进行研究。

相似文献

1
[Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].[接种疫苗的哥伦比亚人与具有登革热免疫力的未接种疫苗者体内的黄热病病毒17D中和抗体]
Rev Salud Publica (Bogota). 2008 Nov-Dec;10(5):796-807. doi: 10.1590/s0124-00642008000500012.
2
Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.用编码YF-17D抗原的复制缺陷型腺病毒载体进行疫苗接种可诱导小鼠对严重黄热病病毒感染产生持久保护。
PLoS Negl Trop Dis. 2016 Feb 17;10(2):e0004464. doi: 10.1371/journal.pntd.0004464. eCollection 2016 Feb.
3
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.采用加速免疫程序的 CYD 四价登革热疫苗的免疫原性:美国成年人的随机 2 期研究。
BMC Infect Dis. 2018 Sep 21;18(1):475. doi: 10.1186/s12879-018-3389-x.
4
Yellow fever (YF) vaccination does not increase dengue severity: A retrospective study based on 11,448 dengue notifications in a YF and dengue endemic region.黄热病(YF)疫苗接种不会加重登革热的严重程度:基于 YF 和登革热流行地区 11448 例登革热报告的回顾性研究。
Travel Med Infect Dis. 2019 Jul-Aug;30:25-31. doi: 10.1016/j.tmaid.2019.05.002. Epub 2019 May 8.
5
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.免疫激活会改变对黄热病17D疫苗的细胞和体液反应。
J Clin Invest. 2014 Jul;124(7):3147-58. doi: 10.1172/JCI75429. Epub 2014 Jun 9.
6
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.减毒活嵌合黄热2型登革热疫苗(ChimeriVax-DEN2):安全性和免疫原性的I期临床试验:黄热预免疫对诱导针对所有4种登革热血清型的交叉中和抗体反应的影响。
Hum Vaccin. 2006 Mar-Apr;2(2):60-7. doi: 10.4161/hv.2.2.2555. Epub 2006 Mar 15.
7
MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination.用于检测黄热病疫苗接种后抗体的MAC-ELISA和ELISA抑制法
J Virol Methods. 2003 Jun 30;110(2):179-84. doi: 10.1016/s0166-0934(03)00128-9.
8
Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.在马里的一次预防免疫活动后,115 名 HIV 感染者中的黄热病疫苗的免疫原性和安全性。
Trans R Soc Trop Med Hyg. 2012 Jul;106(7):437-44. doi: 10.1016/j.trstmh.2012.04.002. Epub 2012 May 22.
9
Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.黄热病病毒特异性中和抗体在接种疫苗后在美国旅行者中的持久性。
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay108.
10
Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.在哥伦比亚和秘鲁12至13个月大的健康幼儿中,黄热病疫苗(Stamaril)与一种四价登革热候选疫苗同时接种时的免疫原性和安全性:一项随机试验。
Pediatr Infect Dis J. 2016 Oct;35(10):1140-7. doi: 10.1097/INF.0000000000001250.

引用本文的文献

1
Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses.黄热病病毒疫苗接种:阐明强大的人类免疫反应的典范模型。
Hum Vaccin Immunother. 2021 Aug 3;17(8):2471-2481. doi: 10.1080/21645515.2021.1891752. Epub 2021 Apr 28.
2
Duration of seropositivity following yellow fever vaccination in U.S. military service members.黄热病疫苗接种后在美国军人中血清阳性的持续时间。
Vaccine. 2020 Dec 14;38(52):8286-8291. doi: 10.1016/j.vaccine.2020.11.022. Epub 2020 Nov 22.
3
Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
黄热病毒 17D 疫苗接种者在非流行地区的中和抗体反应持久性。
J Infect Dis. 2020 Jun 11;221(12):2018-2025. doi: 10.1093/infdis/jiz374.
4
Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.黄热病病毒特异性中和抗体在接种疫苗后在美国旅行者中的持久性。
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay108.
5
Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults.既往接种过疫苗的成年人中黄热病病毒中和抗体的流行率和滴度
Rev Inst Med Trop Sao Paulo. 2017 Apr 3;59:e2. doi: 10.1590/S1678-9946201759002.
6
Questions regarding the safety and duration of immunity following live yellow fever vaccination.关于黄热病活疫苗接种后的安全性和免疫持续时间的问题。
Expert Rev Vaccines. 2016 Dec;15(12):1519-1533. doi: 10.1080/14760584.2016.1198259. Epub 2016 Jun 20.
7
A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination.单次17D黄热病疫苗接种可提供终身免疫;接种疫苗后黄热病特异性中和抗体及T细胞反应的特征分析
PLoS One. 2016 Mar 15;11(3):e0149871. doi: 10.1371/journal.pone.0149871. eCollection 2016.
8
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.黄热病疫苗接种后的效力和免疫持续时间:关于每 10 年加强免疫的必要性的系统评价。
Am J Trop Med Hyg. 2013 Sep;89(3):434-44. doi: 10.4269/ajtmh.13-0264.
9
Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.描述在巴西累西腓进行的 17DD 黄热病疫苗前瞻性队列研究。
Am J Trop Med Hyg. 2011 Oct;85(4):739-47. doi: 10.4269/ajtmh.2011.10-0496.
10
Anamnestic immune response to dengue and decreased severity of yellow Fever.对登革热的回忆性免疫反应与黄热病严重程度降低
J Glob Infect Dis. 2009 Jul;1(2):111-6. doi: 10.4103/0974-777X.56257.